Tomocube토모큐브

Tomocube remains loss-making with revenue growing fast, and its shares are well below their 52-week high.

Tomocube, a Korean maker of optical imaging and precision medical devices, reported trailing-twelve-month revenue of ₩15.2B to H1 2026 against an operating loss of ₩3.9B. Its 2025 revenue rose 90.4% to ₩11.3B, but losses were still large, and the shares closed at ₩31,250, about 33% lower over one year. The company profile and news headlines are not in the data, so the business description rests on the sector label alone.

What stands out

• Revenue reached ₩15.2B on a trailing basis to H1 2026, up from ₩11.3B in 2025 and ₩5.9B in 2024.
• Operating margin improved from -147.8% in 2024 to -49.3% in 2025 and -25.5% on a trailing basis, but the company still lost money at every level.
• Free cash flow was about -₩4.1B on a trailing basis, while cash stood at ₩17.4B and reported borrowings were null, so the balance sheet shows low leverage (liabilities to equity 9.5%).
• Valuation is high against peers: price-to-book is 11.1x versus 3.3x to 7.7x for the listed peers, and price-to-earnings is not meaningful because earnings are negative.
• The share price is up 14.7% over one month but down 10.1% over three months and 32.9% over one year, trading between ₩26,000 and ₩67,800 over the past 52 weeks.

What to watch

• Next quarterly and half-year results, to see whether the operating loss keeps narrowing as revenue grows.
• Trailing free cash flow is negative; watch whether cash of ₩17.4B is sufficient to fund losses without new financing.
• News headlines and foreign ownership or short-selling data are not in the data provided, so these could not be assessed.